Key points are not available for this paper at this time.
Early life stress (ELS) is associated with an increase in expression of inflammatory cytokines and opioid addiction-related behaviors. Maintenance on medication for opioid use disorder (OUD) can opposingly affect these endpoints. The study aimed to determine whether a history of ELS is associated with a distinct inflammatory and/or neurofunctional phenotype within a population of individuals maintained on buprenorphine for OUD. In this secondary analysis of 21 adults (16M/5F), High and Low ELS groups were determined by number of items endorsed on the Trauma History Questionnaire occurring before 18 years old. Peripheral blood levels of 10 cytokines, CRP, LBP, and MCP-1 were assessed. Participants also completed assessments of six neurofunctional domains: reward, cognition, negative emotionality, interoception, metacognition, and sleep. Individuals in the Low ELS group (n = 11; 9M/2F) experienced a median of 3 range: 0-3 traumatic events and individuals in the High ELS group (n = 10; 7M/3F) experienced a median of 8.5 4-13 traumatic events. ELS groups did not differ with respect to age, sex, buprenorphine dose, BMI, smoking status, psychiatric or substance use disorder comorbidity. Proinflammatory cytokines IFNγ (p < 0.001) and IL-6 (p < 0.0001) were elevated in the High ELS group compared to the Low ELS group. Anti-inflammatory IL-13 was higher in the Low ELS group (p = 0.012). There were no neurofunctional differences between ELS groups. Results extend previous findings of an ELS-associated pro-inflammatory state to this OUD treatment population. Future work with larger samples balanced by sex may inform precision medicine strategies to tailor buprenorphine-based OUD treatment to individuals' biopsychosocial needs.
Marcus et al. (Tue,) studied this question.